Dow Today: Pfizer (PFE) Lower

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

The Dow Jones Industrial Average ( ^DJI) is trading down 120.0 points (-0.7%) at 15,888 as of Tuesday, Dec 3, 2013, 1:10 p.m. ET. During this time, 204.1 million shares of the 30 Dow components have changed hands vs. an average daily trading volume of 375.9 million. The NYSE advances/declines ratio sits at 938 issues advancing vs. 1,974 declining with 133 unchanged.
  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Holding back the Dow today is Pfizer (NYSE: PFE), which is lagging the broader Dow index with a 46-cent decline (-1.5%) bringing the stock to $31.36. This single loss is lowering the Dow Jones Industrial Average by 3.48 points or roughly accounting for 2.9% of the Dow's overall loss. Volume for Pfizer currently sits at 19.5 million shares traded vs. an average daily trading volume of 25.3 million shares.

Pfizer has a market cap of $205.64 billion and is part of the health care sector and drugs industry. Shares are up 26.5% year to date as of Monday's close. The stock's dividend yield sits at 3%.

Pfizer Inc., a biopharmaceutical company, discovers, develops, manufactures, and sells medicines for people and animals worldwide. The company has a P/E ratio of 21, above the S&P 500 P/E ratio of 17.7.

TheStreet Ratings rates Pfizer as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, solid stock price performance, good cash flow from operations and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

The 6 Medications Being Used to Tackle the Opioid Epidemic

Dow, S&P 500 Set New Records as Fed Moves to Unwind Balance Sheet

Stocks In Negative Territory as Chances for December Hike Surge

The Wait for 'Milestone' Fed Meeting Keeps Stocks in Flux